Corvus Pharmaceuticals, Inc. (CRVS) P/B ratio

P/B ratio today
13.3×

Corvus Pharmaceuticals, Inc. (CRVS) trades at 13.3× its book value per share at the end of fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/B ratio was 10.0×. That is 0.1% higher than the 10.0× of fiscal 2024. Figures as of 18 Nov 2026, 11:58 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

P/B ratio today
13.3×
P/B ratio, fiscal 2025
10.0×
Change on fiscal 2024
+0.1%
Highest on record
10.0×fiscal 2025
Lowest on record
0.7×fiscal 2022
Fiscal years on record
72019–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Corvus Pharmaceuticals, Inc. P/B ratio, in more detail

Today's figure is 32.1% above the fiscal 2025 year-end.

Across the 7 fiscal year-ends on record (2019–2025), the highest was 10.0× in fiscal 2025 and the lowest 0.7× in fiscal 2022. Today's P/B ratio is above every one of the 7 fiscal year-ends on record; their median is 2.2×.

History · 7 fiscal years

P/B ratio at each fiscal year-end

The last point is today's figure; the others are fiscal year-ends.

Corvus Pharmaceuticals, Inc. P/B ratio, year by year

Corvus Pharmaceuticals, Inc. (CRVS) P/B ratio by fiscal year
Fiscal yearP/B ratioChangeYear endedShare price at year-endBook value per share
Today13.3×—$10.17—
202510.0× 0.1% up$7.70$0.77
202410.0× 358.5% up$5.35$0.53
20232.2× 209.9% up$1.76$0.81
20220.7× 32.1% down$0.85$1.21
20211.0× 28.6% down$2.41$2.32
20201.5× 35.2% down$3.56$2.45
20192.2×—$5.44$2.42
2018——$3.67—
2017——$10.36—
2016——$14.30—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B.

How to read it

It compares the price with the accounting value of what the company owns net of what it owes, and matters most for banks, insurers and other balance-sheet businesses.

More on CRVS

Corvus Pharmaceuticals, Inc., figure by figure

Corvus Pharmaceuticals, Inc. (CRVS) overview: price, valuation and scorecard

Corvus Pharmaceuticals, Inc. P/B ratio: questions and answers

What is Corvus Pharmaceuticals, Inc.'s P/B ratio?

Corvus Pharmaceuticals, Inc. (CRVS) trades at 13.3× its book value per share at the end of fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/B ratio was 10.0×. That is 0.1% higher than the 10.0× of fiscal 2024.

Is Corvus Pharmaceuticals, Inc.'s P/B ratio high or low compared with its own history?

Today's P/B ratio is above every one of the 7 fiscal year-ends on record; their median is 2.2×.

What are the highest and lowest P/B ratio figures on record for Corvus Pharmaceuticals, Inc.?

Across the 7 fiscal year-ends on record (2019–2025), the highest was 10.0× in fiscal 2025 and the lowest 0.7× in fiscal 2022.

How is Corvus Pharmaceuticals, Inc.'s P/B ratio calculated?

The P/B ratio is the share price divided by book value per share — shareholders' equity on the balance sheet divided by the share count — at each fiscal year-end; a year with negative equity has no P/B. For Corvus Pharmaceuticals, Inc. it is on record here for 7 fiscal years, 2019 to 2025.

Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Corvus Pharmaceuticals, Inc. (CRVS) P/B ratio”, data as of 18 November 2026. https://funkfolio.com/stock/CRVS/pb-ratio

Underlying data: the company's filings with the SEC and Yahoo Finance.